June Approval Likely for Entresto as It Clears Key Panel; HFpEF Use OK’ed Too

Novartis’ sacubitril valsartan sodium hydrate, known as Entresto overseas, has passed a key health ministry panel for the treatment of chronic heart failure (HF) including both of two major subtypes, putting it line for official approval as early as June...read more